跳至主要内容
临床试验/EUCTR2008-000906-35-LV
EUCTR2008-000906-35-LV进行中(未招募)1 期

A Prospective, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of BAY 41-6551 as Adjunctive Therapy in Intubated and Mechanically-Ventilated Patients with Gram-Negative Pneumonia

Bayer Schering Pharma0 个研究点目标入组 712 人开始时间: 2008年10月14日最近更新:
适应症

试验速览

阶段
1 期
状态
进行中(未招募)
发起方
入组人数
712

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

入选标准

  • The main inclusion criteria are:
  • Males and non-pregnant, non-lactating females, 18 years of age or older
  • Intubated and mechanically-ventilated
  • Diagnosis of pneumonia defined as presence of a new or progressive infiltrate(s) on chest radiograph and presence of Gram-negative organism(s) by either Gram stain or culture of respiratory secretions
  • CPIS of at least 6
  • At least two risk factors for multi-drug resistant organisms
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range
  • F.1.3 Elderly (>=65 years) yes
  • F.1.3.1 Number of subjects for this age range

排除标准

  • The main exclusion criteria are:
  • Known local or systemic hypersensitivity to amikacin, other aminoglycosides, or components of the amikacin sulfate solution for inhalation
  • Has received antibiotic therapy for Gram-negative pneumonia for greater than 24 hours at the time of randomization
  • Primary lung cancer or another malignancy metastatic to the lungs or other known endobronchial obstructions
  • Known or suspected active tuberculosis, cystic fibrosis, human immunodeficiency virus (HIV) infection with CD 4 count < 200 cell/mm3, or invasive fungal infection of the lung
  • Has had a stroke within five days
  • Burns greater than 40% of total body surface area
  • Screening serum creatinine > 2 mg/dL (177 µmol/L)
  • Neutropenia (Screening ANC < 103 neutrophils/mm3), stem cell transplant
  • Has been on mechanical ventilation for > 28 days
  • Is participating in or has participated in other investigational interventional studies within the last 28 days prior to study treatment
  • Presence of any concomitant condition that, in the opinion of the investigator, would preclude completion of study evaluations or make it unlikely that the contemplated course of therapy and follow-up could be completed
  • Positive serum ß-hCG pregnancy test

研究者

发起方
Bayer Schering Pharma

相似试验

进行中(未招募)
1 期
A study to test the safety and effectiveness of Bay 41-6551 as additional therapy to standard of care antimicrobial treatment in patients who have Gram-Negative Pneumonia and are intubated and mechanially ventilated.Gram-negative pneumoniaMedDRA version: 17.1Level: LLTClassification code 10035701Term: Pneumonia gram-negative bacterial NOSSystem Organ Class: 100000004862
EUCTR2008-000906-35-BEBayer Healthcare AG662
进行中(未招募)
1 期
A Prospective, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group,Multicenter Study of the Efficacy and Safety of Dapoxetine in Men With PrematureEjaculation and Concomitant Erectile Dysfunction Treated With aPhosphodiesterase-5 Inhibitor - COUPLEPremature ejaculation
EUCTR2009-013616-12-FRJanssen-Cilag International NV, Turnhoutseweg 30, 2340 Beerse, Belgium
进行中(未招募)
1 期
A study to test the safety and effectiveness of Bay 41-6551 as additional therapy to standard of care antimicrobial treatment in patients who have Gram-Negative Pneumonia and are intubated and mechanially ventilated.Gram-negative pneumoniaMedDRA version: 20.1 Level: LLT Classification code 10035701 Term: Pneumonia gram-negative bacterial NOS System Organ Class: 100000004862
EUCTR2008-000906-35-PTBayer AG712
进行中(未招募)
1 期
A Prospective, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of BAY 41-6551 as Adjunctive Therapy in Intubated and Mechanically-Ventilated Patients with Gram-Negative PneumoniaGram-negaive pneumonia
EUCTR2008-000906-35-CZBayer Schering Pharma AG712
进行中(未招募)
1 期
A study to test the safety and effectiveness of Bay 41-6551 as additional therapy to standard of care antimicrobial treatment in patients who have Gram-Negative Pneumonia and are intubated and mechanially ventilated.Gram-negative pneumoniaMedDRA version: 20.1Level: LLTClassification code 10035701Term: Pneumonia gram-negative bacterial NOSSystem Organ Class: 100000004862
EUCTR2008-000906-35-NLBayer AG362